SUN PHARMA in the news
Specialty generic pharmaceuticals manufacture
Tamtam found 20 recent articles about SUN PHARMA.
- अमीर निवेशकों का पोर्टफोलियो 10 लाख करोड़ के पार, सन फार्मा पर सबसे बड़ा दांव, सुजलॉन से बनाई दूरी
Indian High Net Worth Individuals' investment portfolios crossed 10 trillion rupees by September 2026, driven by increased stakes in healthcare, banking, and consumer sectors, with Sun Pharma being a top pick.
- Sun Pharmaceutical Industries advances Wednesday, outperforms competitors
Sun Pharmaceutical Industries' shares advanced slightly on Wednesday despite a down market, though they remain below their 52-week high.
- Indian drugmakers take generic semaglutide battle to overseas markets
Indian pharmaceutical companies are aggressively expanding into international markets with generic semaglutide, capitalizing on expiring patents and seeking new growth avenues amid increasing domestic competition.
- Sun Pharmaceutical Industries climbs Tuesday, underperforms market
Sun Pharmaceutical Industries' shares saw a slight increase on Tuesday but underperformed the overall market.
- Sun Pharma seeks $4 bln loan to refinance Organon deal- ET
Sun Pharma is securing a $4 billion loan to refinance its acquisition of Organon & Co.
- Sun Pharma Plans $4 Billion Loan To Refinance $11.75 Billion Organon Acquisition
Sun Pharma plans a $4 billion syndicated loan to refinance bridge debt for its $11.75 billion acquisition of Organon & Co., supported by stable investment-grade credit ratings.
- ऑर्गेनॉन अधिग्रहण के बाद सन फार्मा का बड़ा प्लान, 5 बैंकों से जुटाएगी 4 अरब डॉलर
Sun Pharma plans to raise $4 billion from five international banks to restructure the funding for its $11.75 billion acquisition of Organon, replacing short-term bridge loans with longer-term debt and exploring other financing options.
- Sun Pharma lines up $4bn 5-bank loan for Organon purchase
Sun Pharma is obtaining a $4 billion loan from five banks to finance its $11.75 billion acquisition of Organon & Co.
- सितंबर तिमाही में इन 5 कंपनियों के प्रमोटर्स ने घटाई हिस्सेदारी, फार्मा सेक्टर की कंपनी में बेचा 8% तक का निवेश
Promoters of five companies, including Sun Pharmaceutical Industries and Adani Enterprises, reduced their holdings in the September 2026 quarter.
- Sun Pharma eyes $4 billion loan for Organon buy, five banks likely to anchor refinancing
Sun Pharma is securing a $4 billion syndicated loan to refinance its acquisition of Organon, with five banks leading the financing and exploring additional funding avenues.
- Sun Pharma stock: Nomura trims target as specialty growth slows
Nomura lowered Sun Pharma's target price to INR 2,260 due to slowed specialty growth, despite robust Indian sales and an anticipated Organon acquisition.
- Sensex rebounds over 280 points, Nifty tops 25,300; Bajaj twins gain, M&M, Sun Pharma fall
Indian equity markets recovered on November 12, with Sensex and Nifty rising due to financial and consumer stocks, while Sun Pharma experienced a decline.
- NPPA Sets Sun Pharma's Diclofenac Gel Price at Rs 6.25 Per Gram
NPPA has fixed the price of Sun Pharma's Diclofenac Gel at Rs 6.25 per gram through a corrigendum.
- Deven Choksey prefers Sun Pharma, Cipla for fresh buying; sees upside in Indian IT
Deven Choksey of DRChoksey Finserv favors Sun Pharma and Cipla for new investments, citing their strong position in generic drug manufacturing and export potential, while also being positive on Indian IT companies.
- 15 से 20% तक चढ़ सकते हैं ये 3 फार्मा स्टॉक, सन फार्मा और Cipla पर एक्सपर्ट ने जताया भरोसा
Market expert Deven Choksey recommends Sun Pharma, Cipla, and Dr. Reddy's Laboratories for new buys in the pharma sector, anticipating a 15-20% upside, while advising caution on Divi's Labs and Laurus Labs due to high valuations.
- Weekly Recap: Eye-product halt at Assam plant and 32% Q2 profit fall
Sun Pharmaceutical Industries faced a production halt for eye products at its Assam plant due to quality issues and reported a 32% drop in Q2 profit, despite growth in India formulation sales and new product launches.
- SPARC Share Price: Sun Pharma Advanced Research Shares
Sun Pharma Advanced Research's share price saw an 11% intraday jump on November 9, 2026, driven by sector strength and momentum, despite no specific company news.
- Diwali Muhurat Trading 2026: Tata Steel, Sun Pharma among top five gainers of Nifty 50
Tata Steel and Sun Pharma led the Nifty 50 gains during the special Diwali Muhurat Trading 2026 session, with the market opening higher.
- Muhurat Trading Outperformers in the Diwali Muhurat Session
On November 8, 2026, the Diwali Muhurat trading session saw various outperformers including Tata Steel and Sun Pharma, while Finolex Cables notably rose 15.22% on strong Q2 results.
- Muhurat trading: Sensex up 320 pts, Nifty crosses 25,100; Tata Steel, Sun Pharma among top gainers
The Indian stock market saw a positive start to Muhurat trading with Sensex up 320 points and Nifty above 25,100, and Sun Pharma was among the top gainers.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like SUN PHARMA?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies